Johnson & Johnson presented new clinical data for its TECNIS PureSee intra‑ocular lens (IOL) at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 meeting, which began on April 10, 2026. The presentation marked the first public disclosure of performance results for the lens since its FDA approval on March 12, 2026.
The data came from two studies: a post‑market observation study of 293 patients in Europe and Asia‑Pacific, and a U.S. prospective, randomized trial of 200 patients. Results demonstrated excellent contrast sensitivity, an extended range of vision, and low rates of visual disturbances. The TECNIS PureSee is a purely refractive extended‑depth‑of‑focus (EDOF) design that does not use diffractive rings and is the first FDA‑approved EDOF lens without a contrast‑sensitivity warning.
Paul Lisenby, Global Head of Research and Development for Vision, said the data “confirms that TECNIS PureSee IOL provides patients with high contrast sensitivity and visual acuity across distances, with low levels of visual disturbances. This evidence underscores our commitment to advancing innovation through rigorous clinical research—extending the range of vision for our patients and reinforcing surgeon confidence.”
The new evidence is expected to support surgeon adoption and market penetration in the premium cataract surgery segment. By differentiating itself from competing premium IOLs with its refractive design and preserved contrast sensitivity, the lens positions Johnson & Johnson to strengthen its Vision business within MedTech. MedTech worldwide operational sales grew 5.4% in Q4 2025, and the company’s 2026 guidance signals continued growth, indicating that the new data could contribute to future sales momentum.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.